Equillium (EQ) Stock Price, News & Analysis

Company Overview

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $0.86 to $0.90
• 50-Day Range: $0.60 to $0.94
• 52-Week Range: $0.49 to $3.25
• Volume: 39,719 shs
• Average Volume: 2.19 million shs
• Market Capitalization: $31.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Equillium Stock Analysis - MarketRank™

Equillium scored higher than 54% of companies evaluated by MarketBeat, and ranked 689th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Equillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Equillium has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Equillium are expected to decrease in the coming year, from $0.14 to ($0.81) per share.

Price to Book Value per Share Ratio

Equillium has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.54% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently increased by 245.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Equillium does not currently pay a dividend.

Dividend Growth

Equillium does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.54% of the float of Equillium has been sold short.

Short Interest Ratio / Days to Cover

Equillium has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Equillium has recently increased by 245.56%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Equillium has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

Search Interest

4 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Equillium insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,500.00 in company stock.

Percentage Held by Insiders

30.30% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.05% of the stock of Equillium is held by institutions.

EQ Stock Analysis - Frequently Asked Questions

How have EQ shares performed this year?

Equillium's stock was trading at $0.7482 at the start of the year. Since then, EQ shares have increased by 17.6% and is now trading at $0.88.
View the best growth stocks for 2025 here.

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.01. Equillium had a negative net margin of 10.05% and a negative trailing twelve-month return on equity of 20.68%.

When did Equillium IPO?

Equillium (EQ) raised $70 million in an initial public offering on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO.

Who are Equillium's major shareholders?

Equillium's top institutional investors include Takeda Pharmaceutical Co. Ltd. (5.15%), Renaissance Technologies LLC (0.74%), DCF Advisers LLC (0.18%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Christine Zedelmayer, Jason A Keyes and Penny Tom.
View institutional ownership trends.

How do I buy shares of Equillium?

Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Equillium own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include NVIDIA (NVDA), Meta Platforms (META), Bank of America (BAC), Advanced Micro Devices (AMD), AbbVie (ABBV), Tilray (TLRY) and Carnival Co. & (CCL).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 2/21/2025
• Next Earnings (Estimated): 3/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EQ
• CUSIP: N/A
• CIK: 1746466
• Web: equilliumbio.com
• Phone: (858) 240-1200
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +468.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 6.29
• P/E Growth: N/A
• Net Income: $-13,340,000.00
• Net Margins: -10.05%
• Pretax Margin: -10.02%
• Return on Equity: -20.68%
• Return on Assets: -10.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.04
• Quick Ratio: 3.04

Sales & Book Value

• Annual Sales: $36.08 million
• Price / Sales: 0.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 1.38

Miscellaneous

• Outstanding Shares: 35,430,000
• Free Float: 24,695,000
• Market Cap: $31.18 million
• Optionable: Not Optionable
• Beta: 1.79